Please assess the completion status of the following clinical trial:

Trial Title: Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent.~* Men and women \>/=50 years of age.~* Active primary or recurrent subfoveal CNV lesions secondary to AMD, including juxtafoveal lesions that affect the fovea as evidenced by Fluorescein angiography (FA) in the study eye.~* ETDRS Best-Corrected Visual Acuity letter score of 73 to 25 (= Acuity of 20/40 to 20/320) in the study eye at 4 meters.~* Willing, committed, and able to return for ALL clinic visits and complete all study-related procedures.~* Able to read, (or, if unable to read due to visual impairment, be read to verbatim by the person administering the informed consent or a family member) understand and willing to sign the informed consent form.~Exclusion Criteria:~* Any prior ocular (in the study eye) or systemic treatment or surgery for neovascular AMD, except dietary supplements or vitamins.~* Any prior or concomitant therapy with another investigational agent to treat neovascular AMD in the study eye.~* Any prior treatment with anti-VEGF agents in the study eye.~* Total lesion size \>12 disc areas (30.5 mm, including blood, scars and neovascularization) as assessed by FA in the study eye.~* Subretinal hemorrhages that is either 50% or more of the total lesion area, or if the blood is under the fovea and is 1 or more disc areas in size in the study eye (if the blood is under the fovea, then the fovea must be surrounded by 270 degrees by visible CNV).~* Scar or fibrosis making up \>50% of the total lesion in the study eye.~* Scar, fibrosis, or atrophy involving the center of the fovea in the study eye.~* Presence of retinal pigment epithelial tears or rips involving the macula in the study eye.~* History of any vitreous hemorrhage within 4 weeks prior to Visit 1 in the study eye.~* Presence of other causes of CNV in the study eye.~* Prior vitrectomy in the study eye.~* History of retinal detachment or treatment or surgery for retinal detachment in the study eye.~* Any history of macular hole of stage 2 and above in the study eye.~* Any intraocular or periocular surgery within 3 months of Day 1 on the study eye, except lid surgery, which may not have taken place within 1 month of Day 1, as long as it is unlikely to interfere with the injection.~* History or clinical evidence of diabetic retinopathy, diabetic macular edema or any retinal vascular disease other than AMD in either eye.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ranibizumab 0.5mg Q4 (Type: ACTIVE_COMPARATOR): Participants received a 0.5 mg dose of Ranibizumab via intravitreal (IVT) injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
- Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4 (Type: EXPERIMENTAL): Participants received a 2.0 mg dose of Aflibercept Injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
- Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4 (Type: EXPERIMENTAL): Participants received a 0.5 mg dose of Aflibercept Injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
- Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8 (Type: EXPERIMENTAL): Participants received a 2.0 mg dose of Aflibercept Injection administered every 8 weeks (including one additional 2,0 mg dose at Week 4) for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).